Takeaways from last week’s gene patenting decision

The following is an edited excerpt.

The Supreme Court on Thursday issued a ruling that bans the patenting of naturally occurring genes but allows edited or artificially created DNA to be patented. What does the decision mean for patients and the biotech industry? We talked to experts about some of the big takeaways:

  1. Naturally occurring genes are no longer patentable.
  2. Synthetic DNA is still fair game.
  3. Prices for testing genetic diseases are already falling.
  4. It could get easier to sequence whole genomes.
  5. There are implications beyond human genes.
  6. Whether Myriad’s secret patient database will be opened is unclear.
  7.  The ruling might not actually matter that much.

Read the full story here: 7 Takeaways From Supreme Court’s Gene Patent Decision

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend